Vijverberg Maarten A, Verhamme Luc, van de Pol Pascal, Kunst Henricus P M, Mylanus Emmanuel A M, Hol Myrthe K S
Department of Otorhinolaryngology, Donders Center for Neurosciences, Radboud University Medical Center, PO-box 9101, Philips van Leydenlaan 15, 6500 HB, Nijmegen, The Netherlands.
Department of Maxillo-Facial Surgery, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.
Eur Arch Otorhinolaryngol. 2019 Apr;276(4):1017-1027. doi: 10.1007/s00405-019-05311-0. Epub 2019 Feb 5.
Not long after the introduction of osseointegrated implants outside the oral cavity, auricular prostheses are retrained on osseointegrated implants. New insights have been gained with the next-generation percutaneous osseointegrated titanium implants for bone conduction hearing since its introduction in 2010. As a result, the same technology was introduced in the Vistafix system (VXI implant) to retain auricular prostheses. The aim of this study is to evaluate the surgical procedure, clinical outcome, and satisfaction of the patient of osseointegration-retained auricular prosthesis using VXI implants.
11 patients who received an auricular prosthesis using VXI implants between December 2012 and November 2017 were evaluated retrospectively. The patient's medical files were reviewed to assess clinical complications and the necessity for revision surgery. The subjective outcome was measured using the Glasgow benefit inventory (GBI).
In total, 31 implants were placed in 11 patients. None of these implants were lost nor revision surgery needed. An adverse skin reaction was observed in 13.0% of the implants and in 27.2% of the patients, adequately treated with an antibiotic ointment. The average follow-up time was 2 years and 7 months. The GBI displayed a positive score in every patient.
The VXI implants used are a safe and reliable treatment option for retaining auricular prostheses in patients with an absent auricle. Patients were satisfied with their auricular prosthesis and showed benefit in quality of life. Studies with larger numbers and preferably a prospective character are needed to draw statistically significant conclusions.
在口腔外引入骨整合植入物后不久,耳廓假体就开始采用骨整合植入物进行修复。自2010年推出用于骨传导听力的下一代经皮骨整合钛植入物以来,人们获得了新的见解。因此,相同技术被引入Vistafix系统(VXI植入物)以固定耳廓假体。本研究的目的是评估使用VXI植入物进行骨整合固定耳廓假体的手术过程、临床结果以及患者满意度。
回顾性评估了2012年12月至2017年11月期间11例接受VXI植入物耳廓假体的患者。查阅患者的病历以评估临床并发症和翻修手术的必要性。使用格拉斯哥效益量表(GBI)测量主观结果。
11例患者共植入31枚植入物。这些植入物均未丢失,也无需翻修手术。13.0%的植入物和27.2%的患者出现了皮肤不良反应,使用抗生素软膏进行了充分治疗。平均随访时间为2年7个月。每位患者的GBI评分均为阳性。
所使用的VXI植入物是为无耳廓患者固定耳廓假体的一种安全可靠的治疗选择。患者对其耳廓假体感到满意,生活质量得到改善。需要进行更大规模且最好具有前瞻性的研究才能得出具有统计学意义的结论。